Whilst our attention has been on COVID-19 recent research has shown that T4 proliferates cancer by acting on the "integrin αvβ3 receptor", a receptor on the cell membrane. At physiological levels T4 (and not T3) is the active hormone.
Research outcomes are complex but on balance high T4 levels are more carcinogenic than low T4. Studies indicate that levothyroxine monotherapy is associated with increased cancer cases and mortality rates.
This is a sensitive and complex issue which I feel needs to be addressed urgently. I have put a full description along with the evidence here: ibshypo.com/index.php/thyro... with an attempt to estimate the number of deaths resulting from monotherapy as compared to combination therapy.
I have always been in favour of using levothyroxine when it works for the patient, usually in simple cases of primary hypothyroidism. In the light of recent research, I feel levothyroxine / liothyronine combination therapy should now be the usual treatment for primary hypothyroidism. A relatively small amount of liothyronine would avoid having above average fT4 levels as well as giving symptomatic improvement for some patients.
The levothyroxine Patient Information Leaflet (PIL) should include a warning to consult your doctor if you are taking levothyroxine and have cancer. This will enable the oncologist to consider on a case-by-case basis whether thyroid hormone treatment needs to change.
As most of you are aware I am a patient, not a doctor.